Why Is BIOCRYST PHARMACEUTI (BCRX) Stock Down Today?
By the Top Tier Newswire AI Desk · September 9, 2026 at 12:26 AM ET · reviewed against 3 wire stories
BIOCRYST PHARMACEUTI (BCRX) is down -8.99% in the latest session. Our newswire has captured 3 stories on BCRX across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 51/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
BCRX stock fell 8.99% to $9.07 on Thursday, marking one of its worst single-day declines in over six months. The drop came after Pharvaris reported positive results from its late-stage trial for a rare swelling disease, potentially challenging BioCryst’s market position in the hereditary angioedema space. The news overshadowed recent positive developments, including a partnership with CareMed and ongoing analyst optimism about the company’s drug pipeline.
What Happened
Pharvaris announced on Tuesday that its experimental once-daily pill reduced monthly swelling attacks by 83% in patients with hereditary angioedema compared to a placebo. This result could signal a new competitive threat in a market where BioCryst’s Orladeyo is a key player. The news appeared to trigger a sell-off as investors reevaluated the company’s long-term prospects. Meanwhile, BioCryst announced that CareMed would serve as a national pharmacy partner for Orladeyo, expanding its distribution network. However, this positive development failed to offset the market’s reaction to the Pharvaris update.
BioCryst also recently received approval for Orladeyo in Japan for pediatric HAE patients. Despite this, the stock’s sharp decline suggests the market is prioritizing the competitive risk from Pharvaris over near-term operational progress.
What The Data Shows
BCRX closed at $9.07, down from a 52-week high of $11.22. The stock has traded between $6.00 and $11.22 over the past year. On September 8, the stock printed six fresh 52-week lows and two 52-week highs, highlighting the volatile nature of its recent price action. The company has a market cap of $2.5B and remains unprofitable, with a trailing twelve-month net margin of -40.9% and revenue up 68.7% year to date. Its beta of 0.56 indicates it is less volatile than the broader market.
What To Watch
BioCryst has no upcoming earnings date scheduled. Investors should monitor the breadth of analyst coverage and any further developments in the HAE drug space, particularly how Pharvaris’ trial results might influence regulatory or commercial timelines.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BCRX · Sep 9 session (5-min) · -2.82% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 3 stories · 51/100 neutral
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
4d agoStocktwits NewsBEARISH 28Product/PR
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease
Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients.
4d agoBusiness InsiderBULLISH 63Product/PR
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio
NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo ® (berotralstat), a plasma kallikrein inhibitor...
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →